Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Aspira Women's Health Inc. currently has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 4 distinct examiners and 4 distinct art units, indicating a diverse range of active prosecution across multiple specialized examination teams.
BUCHANAN, BAILEY CHEYENNE is the busiest examiner, responsible for 1 pending office action. This examiner handles 1 of the company's 4 total pending office actions, which suggests that the portfolio's current legal challenges are widely dispersed among various office personnel.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 2 (50%) |
| Double-patenting + other | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
| DESAI, ANAND U | 1 | 78.5% | +12.7% |
| REGA, KYLE THOMAS | 1 | 62.7% | +41.4% |
| BARRON, SEAN C | 1 | 52.9% | +30.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17933446 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT HAVING IMPROVED SPECIFICITY AND SENSITIVITY | BUCHANAN, BAILEY CHEYENNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17267947 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT | REGA, KYLE THOMAS | 23d overdue |
| 16793347 | PREDICTIVE BIOMARKERS FOR OVARIAN CANCER | BARRON, SEAN C | 23d |
| 17933446 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT HAVING IMPROVED SPECIFICITY AND SENSITIVITY | BUCHANAN, BAILEY CHEYENNE | — |
| 17800850 | COMPOSITIONS FOR ENDOMETRIOSIS ASSESSMENT HAVING IMPROVED SPECIFICITY | DESAI, ANAND U | — |
| Art Unit | Apps |
|---|---|
| 1758 | 1 |
| 1655 | 1 |
| 1636 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17933446 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT HAVING IMPROVED SPECIFICITY AND SENSITIVITY | BUCHANAN, BAILEY CHEYENNE | 1758 | §101§103§112 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17800850 | COMPOSITIONS FOR ENDOMETRIOSIS ASSESSMENT HAVING IMPROVED SPECIFICITY | DESAI, ANAND U | 1655 | §112 | Non-Final OA | — | Pending | Aug 18, 2022 |
| 17267947 | COMPOSITIONS FOR OVARIAN CANCER ASSESSMENT | REGA, KYLE THOMAS | 1636 | §112 | Non-Final OA | 23d overdue | Pending | Feb 11, 2021 |
| 16793347 | PREDICTIVE BIOMARKERS FOR OVARIAN CANCER | BARRON, SEAN C | 1653 | §103DP | Final Rejection | 23d | Pending | Feb 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial